HIV-1 protease inhibitors (PIs) have long been central to antiretroviral therapy, directly targeting the enzyme responsible for processing viral polyproteins into functional units. Their efficacy, ...
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
More than 40 years of AIDS research has led to significant advancements in treatment and prevention. Drugs to treat the infection continued to improve, as did patient outcomes. But now there's another ...
About 40 million people worldwide are living with HIV infection. In the United Kingdom, there are approximately 100,000 people affected. If the infection is not treated, the body will eventually be ...
On June 5, 1981, national health experts published accounts of a strange infection circulating around Los Angeles. The U.S. Centers for Disease Control and Prevention (CDC) reported on that day that, ...
According to DataM Intelligence, the HIV Therapeutics Market Size grew to USD 37.61 billion in 2024 and is projected to reach USD 57.56 billion by 2033, advancing at a CAGR of 4.8% during the forecast ...
Experts warn that poor sugar control pushes HIV-related health risks higher, leading to faster progression of heart, kidney ...
According to DataM Intelligence, the HIV Therapeutics Market Size grew to USD 37.61 billion in 2024 and is projected to reach USD 57.56 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback